# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Thomas Flaten maintains OptiNose (NASDAQ:OPTN) with a Buy and lowers the price target from $4 to $3.
HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.
Operating Expenses The Company expects total GAAP operating expenses (selling, general & administrative expenses and resear...
OptiNose (NASDAQ:OPTN) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by...